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Abstract  
N-Myc downstream-regulated gene 2 (NDRG2) has been of interest in cancer research in the last 
decade, because a connection between NDRG2 expression level and the ability to be a tumor 
suppressor has been observed. This report is divided into two parts. First part is a review article 
which attempts to accumulate the new knowledge of NDRG2 in cancer from 2010 and till today. 
Not a lot of reviews are seen yet and this is an attempt to fill out this gap in the research 
literature. The second part is an original article about ovarian cancer, a cancer that has yet to 
become a priority in this research area. The article has two parts as well. First, a preliminary 
study of the expression of NDRG2 in both ovarian cancer cell line SKOV-3 and ovarian cancer 
tissue. Second, to our knowledge, the first preliminary study examining the two alternative 
splice forms expressed in ovarian mRNA. The methods used in the original article are real-time 
PCR and the Comparative Ct Method for the first part and for the second part, normal PCR and 
gel electrophoresis. The data found suggest that NDRG2 is downregulated in ovarian cancer and 
that the two alternative splice forms of NDRG2 mRNA are present in ovarian cancer tissue. Even 
though the future holds promise of NDRG2 as a TS-gene and a biomarker for cancer, more 
research is still needed to explore the possibility that NDRG2 can be used as a target for 
treatment for cancer.  
 
I cancer forskningen har N-Myc downstream-regulated gene 2 (NDRG2) været i fokus det sidste 
årti, da en forbindelse mellem NDRG2 ekspressionen og tumor suppressor karakteristika er 
blevet observeret. Denne rapport er delt op i to dele, hvor første del er en review artikel, der 
forsøger at samle den nyeste viden om NDRG2 fra 2010 og til i dag. Der er ikke mange review 
artikler endnu og dette er et forsøg på, at udfylde det hul i litteraturen. Den anden del er en 
original artikel om NDRG2 i ovariecancer, som er en cancerform der endnu ikke er blevet en 
prioritet i dette forsknings område. Denne artikel er også opdelt i to. Først, et indledende studie 
om NDRG2 ekspressionen i både ovarie cellelinjen SKOV-3 og ovariecancer væv. Ydermere er 
det, så vidt vi har kendskab til, første indledende studie som undersøger hvorvidt de to 
alternative mRNA splice former der eksisterer for NDRG2, er udtrykt i ovarie mRNA. Metoderne 
anvendt i original artiklen er real-time PCR og the Comparative Ct Method samt normal PCR og 
gel elektroforese. De data der er genereret antyder, at NDRG2 er nedreguleret i ovariecancer og 
at de to alternative splice former af NDRG2 mRNA er til stede. Selvom fremtiden ser lovende ud i 
forhold til NDRG2 som et TS-gen og som biomarkør for cancer, så er mere forskning nødvendig 
for at udforske de muligheder, hvor NDRG2 kan blive anvendt som et target for cancer 
behandling.  
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Abbreviations 
ATLL – adult T-cell leukemia-lymphoma  
CDK – cyclin dependent kinase 
CDKI – cyclin dependent kinases inhibitor  
CNN1 – CYR61, CTGF (connective tissue growth factor) and NOV (nephroblastoma 
overexpressed)  
ECM – extracellular matrix 
EMT – epithelial-mesenchymal transition 
ERK1/2 – extracellular signal-regulated protein kinase pathway 
FXR – Farnesoid X Receptor 
HIF-1⍺ – hypoxia-inducible factor1-⍺ 
LAP – Latency-associated Peptide 
MAPK – mitogen activated protein kinase  
MMP – metalloproteinase  
NDRG2 – N-Myc downstream regulated gene 2 
PDK1 – Phosphoinositide-dependent kinase-1 
PI3K – phosphatidylinositol 3'-kinase 
PIP2 – phosphatidylinositol 4,5-bisphosphate 
PIP3 – phosphatidylinositol-3,4,5-trisphosphate 
PP2A – protein phosphatase 2A   
PTEN – phosphatase and tensin homologue 
Rb – retinoblastoma protein 
TGF-ẞ – Transforming Growth Factor 
TNF – tumor necrosis factor  
TNM – tumor node metastasis 
TS-gene – tumor suppressor gene  
VEGF – vascular endothelial growth factor 
VHL – von Hippel-Lindau 
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Introduction 
WHO have stated that there worldwide in 2012 were 32.6 million living with cancer, 14.1 million 
got the diagnosis while 8.2 million succumbed to the disease (Globocan). Lung cancer has long 
been the most common cancer in the world and the most frequent in men, while breast cancer 
comes in on a second place over the most common cancers in the world and is the most 
frequent cancer type in women (Globocan).  
In the literature there is described six Hallmarks of cancer1: 1) Sustaining proliferative signaling, 
2) evading growth suppressors, 3) activating invasion and metastasis, 4) enabling replicative 
immortality, 5) inducing angiogenesis and 6) resisting cell death  and it is important to 
understand these to the fullest. In the last decade the gene NDRG2 has been of interest in 
research because it seems to be a tumor suppressor gene (TS-gene) and because it seems to play 
a pivotal role in carcinogenesis.  
Ndrg2 was first found in mice in in 19992. Human NDRG2 was first described in the literature in 
2001 and then again in 2002 and 20033-5. It varies who gets the credit in the literature today. N-
Myc downstream-regulated gene 2 (NDRG2) was so named because its sequence was closely 
related to NDRG16. NDRG2 is part of the NDRG family, which have four members: NDRG1, 
NDRG2, NDRG3 and NDRG4. Furthermore phylogenetic, NDRG1 and NDRG3 belong to one 
subfamily and NDRG2 and NDRG4 belongs to another subfamily4. NDRG2 is shown to have two 
isoforms, one with 371 amino acids4 and one with 357 amino acids3, but this has yet to become a 
priority in the research. The focus point right now is whether NDRG2 can be used as a biomarker 
for cancer and overall survival.  
 
The main emphasis of this report is a review article focusing on NDRG2 role in cancer from 2010 
till present. Furthermore there is a section with background information of some of the 
molecular biology addressed in the review, and in the quest to discover more about NDRG2, a 
preliminary study of NDRG2 expression and NDRG2 alternative splice form expression in ovarian 
cancer has been performed. Lastly is made a statement on how the future could look like in the 
research in NDRG2 to come. In the Appendix is a protocol describing the study, an introduction 
on the chosen method real-time PCR and all the graphs connected to the study in the original 
article. 
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Background  
In the following are different aspects and concepts outlined. These concepts are important for 
the understanding of some of the aspect depicted in the review and original article.  
Cell cycle 
Proliferation is essential for renewal and survival of cells and the regulation of whether a cell 
should step out of the dormant stage G0 depends on a variety of internal and external signals, 
including growth factors and hormones.  The different phases of a cells cycle can shortly be 
summarized to: G1 phase, where initial growth takes place and an ultimately commitment to 
complete division; S phase, where synthesis of DNA takes place; G2 phase, where the cell 
prepares for division and lastly; M phase, where mitosis and cytokinesis takes place. In the midst 
of some of the phases there are so-called checkpoints that have to be succumbed before further 
proliferation, with the checkpoint between G1 and S being the most important.  
Some of the molecules that orchestrate the cell cycle are cyclins and cyclin dependent kinases 
(CDK), and in the different phases there are expressed different cyclins, which in turn binds and 
activate a steady level of distinct CDKs and thus provide a go-ahead signal. In overcoming the 
checkpoint at G1, ample cyclinD must form a complex with CDK4 or CDK67, and these complexes 
of cyclinD/CDK4/6 have a role of phosphorylating Retinoblastoma (Rb) proteins, which then 
dissociates from the transcription factor E2F and thereby activates E2F. Two out of several 
proteins E2F induces expression of, is cyclinE and cyclinA8 and cyclinE is expressed in mid to late 
G1 phase, see figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Showing one facet of a cell cycle – in which phases the cyclins are expressed and how 
Rb is phosforylated
34
. 
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CyclinE form complexes with CDK27 and the complex of cyclinE/CDK2 act as a positive loop 
feedback in phosphorylating more Rb, resulting in acceding the threshold for entering S phase8. 
Throughout S phase and into G2 phase, an accumulation of cyclinA takes place and cyclinA 
functions as a negative loop feedback for E2F as well as forming a complex with CDK1.  
For the cell to move through the checkpoint in G2 and commence mitosis, complexes must be 
formed between cyclinA/B and CDK1, giving the cell time to repair possible damage to the DNA. 
To finish mitosis, cyclinA/B must be degraded8, and parallel to this there has been a 
dephosphorylation of Rb due to degradation of cyclins. This leads the cell back in the G1 phase 
prior to the checkpoint where it determines, on the level of cyclinD/CDK4/6 complexes, whether 
it is to reside to G0 or continue yet another replication8.    
 
Regulation 
Besides positive signals informing the cell to divide, there are always inhibitors present to make 
sure the cell does not proliferate when e.g. there is cellular damage, lack of nutrients or 
exogenous stress signals9. A key regulatory mechanism for cell cycle progression is the 
interaction between CDK and the CDK inhibitors (CDKI) and thus hindrance of complex formation 
between cyclins and CDK and phosphorylation of Rb. The CDKI can be divided into two families: 
the Ink4 (p15, p16, p18 and p19) and the Cip/Kip (p21, p27 and p57)7, see figure 2. One of the 
more prominent CDKI is p21, 
which can bind and down-
regulate both cyclinD/CDK4 
and cyclinE/CDK2. p21s ex-
pression is regulated by e.g. 
p53 due to intracellular DNA 
damage detection and 
Transforming Growth Factor-
ẞ (TGF-ẞ), which register 
extracellular signals10. 
 
TGF-ẞ 
The family of these cytokines consists of three isoforms in humans: TGF-β1, TGF-β2 and TGF-β3. 
They are produced as a precursor molecule in the cytoplasm and forms complexes with Latency-
associated Peptide (LAP) and are subsequent transported to the extracellular space. Here they 
can be activated through numerous pathways, the most researched are proteases11, 
metalloproteinases (MMPs)12 and integrin-ẞ611. When cleaved and thus activated, TGF-ẞ can 
Figure 2 Cell cycle regulation through the CDKI Ink and Kip family
34
. 
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activate two types of serine/threonine kinase receptors. Intracellular in target cells, it will initiate 
different signaling cascades, with one of the more investigated being Smad, which ultimately 
leads to either activation or repression of gene transcription11, see figure 3 for a schematic 
overview.   
Intriguingly it has been shown that TGF-ẞs involvement in cancer is double-sided, where it in the 
early stages of cancer functions as a TS-gene and inhibits proliferation and angiogenesis and 
activates apoptosis. Meanwhile in late stages of cancer it gains oncogenic properties and induces 
proliferation, metastasis, angiogenesis and epithelial to mesenchymal transition (EMT)13, i.e. the 
ability to separate from neighboring cells and thus penetrate into surrounding tissues14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Metalloproteinases  
This brief introduction will only focus on the two gelatinases MMP-2 and MMP-9. These 
proteases are found in the extracellular matrix, (ECM), and as the group name indicates, their 
function is to degrade components of ECM, e.g. gelatin, elastin and collagen12.  The timely 
degradation is important in wound healing, tissue repair and growth15, but in numerous cancers 
there are seen a high expression profile, which results in elevated degradation of the ECM and 
thus elevated levels of e.g. ECM-sequestered VEGF and TGF-ẞ12. There is therefore often a 
parallel between MMP-2/MMP-9 levels and angiogenesis, proliferation, migration and growth12. 
Moreover, there is established a correlation between high level of MMP-2/MMP-9 and tumor 
aggression and poor prognosis. Therefore they are used as biomarkers for various cancer 
forms12. 
Figure 3 Schematic overview of TGF-ẞ synthesis, transport to extracellular space, 
immobilization via binding of the large latent TGF-ẞ binding protein (LTBP) to ECM 
and release due to proteases and activation of TGF-ẞ and lastly binding to TGF-ẞ 
receptors and activation of the intracellular signaling cascade Smad
33
. 
11 
 
 
Epithelial to mesenchymal transition  
EMT is a reversal biologic process where a cell undergo multiple biochemical changes that 
enable it to assume a mesenchymal cell phenotype, which includes enhanced migratory 
capacity, invasiveness, elevated resistance to apoptosis, and increased production of ECM 
components14. Under normal conditions, epithelial cells are anchored to the basement 
membrane and closely connected to neighboring cells through tight junctions encompassing e.g. 
E-cadherin and ẞ-catenin.  EMT begins with the loss of tight junctions, gap junctions and 
degradation of the underlying basement membrane. 
Cell surface proteins like E-cadherin and integrins mediates epithelial connections to neighboring 
cells and the basement membrane, respectively. These are replaced by N-cadherin and other 
integrins that provide more momentary adhesive properties priming the cell for the 
mesenchymal phenotype16.  In many cases, the involved molecular processes that is achieved in 
a epithelial cell transition to a mesenchymal cell, is used as biomarkers to measure the level of 
mesenchymal cells14, see figure 4.  
EMT is under normal conditions activated under e.g. wound healing, where the need for cells to 
migrate is imperative. EMT is however quickly reversed by the initiation of mesenchymal to 
epithelial transition (MET), to re-anchor the cells. In cancer, EMT enables the cells to escape the 
primary tumor site and MET is first accomplished after the cells have migrated to new sites in 
the organism16. 
 
 
VHL, HIF-1α and VEGF 
During normal conditions in the cell, ample oxygen is available and normal processes can occur, 
e.g. ATP production17. The maintenance of oxygen homeostasis is mainly accomplished through 
repression of the hypoxia inducible factor-1alpha (HIF-1⍺), which, under normoxic conditions, is 
Figure 4 Illustrates expressed molecules during an EMT which are used as markers to identify intermediate 
phenotypes and thereby gives an indication of how far along cells are in the transition
14
. 
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done though complex formation between Von Hippel-Lindau suppressor (VHL) and HIF-1⍺, 
mediated by O2. This marks HIF-1⍺ with ubiquitin and leads it to proteasomal degradation. 
When the environment changes to hypoxic, the lack of O2 results in no proteasomal degradation 
of HIF-1⍺, and now HIF-1⍺ moves to the nucleus and induces alternate gene expression to try 
and keep up e.g. ATP production17. An array of approximately 100 hypoxia induced genes covers 
functions involved in angiogenesis, proliferation, erythropoietin, apoptosis and glucose 
metabolism, with a particular key player being vascular endothelial growth factor (VEGF)18,19. 
This relates well with development of carcinogenesis, where, as the tumor grows and become 
solid, the oxygen levels decline, and proliferation attenuates unless e.g. angiogenesis is 
accomplished. As the cancer progress, it is common to see mutations in VHL, ensuring a 
continuous expression of HIF-1⍺18 and for some cancers HIF-1⍺ is being used as an independent 
biomarker for poor prognosis19. Focusing in on growth, Koshiji and colleagues found that HIF-1⍺ 
can induce hypoxia induced growth arrest by derepressing p21 through antagonizing Myc 
binding to the promoter region17.          
Cell cycle arrest is not normally desirable for cancer, and is a control mechanism for normal cells 
that cancer overcomes through other regulations or for some cancers, p21 is exploited because 
of seemingly oncogenic properties of the protein20.  
 
c-Myc 
The Myc family comprises l-Myc, n-Myc and c-Myc, but focus will be on c-Myc, which is an 
oncogene that extremely often is deregulated, or its mRNA stabilized, and thus involved in 
carcinogenesis21. It has been thoroughly investigated for a couple of decades and brought many 
puzzling and seemingly contradictory results, which now is forming a picture of a highly 
pleiotropic transcription factor. It is usually found in complex with Max when bound to the DNA 
sequence 5’-CACGTG-3’, labelled E-box, and the net result being an upregulation of 
transcription. It is however not clear whether it acts directly on DNA or in concert with other 
proteins other than Miz-1 when the net result is a downregulation of transcription22,23.  
In a normal cell, it influences the progression of cell cycle by upregulating E2F, cyclinD, cyclinE 
and downregulates CDKI23 and p2124. Other target genes of c-Myc encompasses those involved 
in apoptosis, protein synthesis, survival, cell adhesion, cytoskeleton, metabolism and miRNA 
expression24. 
It is difficult to accurately place c-Myc action in cancerous cells, since its roles changes 
depending on other factors and level of the molecule21. 
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CYR61  
CYR61 is by newer terms called CCN1 and is part of the family CCN1-6. The acronym is derived 
from CYR61, CTGF (connective tissue growth factor) and NOV (nephroblastoma overexpressed). 
It is a protein that exists in the extracellular matrix where it is responsible for a multitude of 
cellular responses, some with seemingly opposing functions. It mediates signals through 
primarily binding to integrin receptors, and depending on which cell type and receptor type, it 
has been shown to mediate signals involved in angiogenesis, apoptosis, cell survival, 
proliferation, cell cycle arrest, wound healing and regulation of inflammation, invasiveness, 
migration, differentiation and cell adhesion. CYR61 expression is often found to be dysregulated 
in numerous cancers, but similarly here, level of expression and function seemingly depends on 
cancer tissue. When overexpressed in cancer cells from breast, prostate, pancreatic, ovarian, 
squamous and gastric adenocarcinoma, it resulted in a combination of various oncogenic effects, 
such as promotion of tumor growth, proliferation, invasion, apoptosis-resistance, survival, and 
elevated levels of metastasis. Likewise there has been shown a correlation between CYR61 and 
tumor size, TNM stage and poor prognosis in several cancers, including breast, prostate, glioma, 
gastric adenocarcinoma and squamous cell carcinoma25.  
Contradictory to these findings, CYR61 moreover possess tumor suppressor mechanisms like 
inducing apoptosis and suppressing tumor growth, as well as inhibiting proliferation and 
metastasis. Puzzling, this has also been shown in prostate cancer, but here the high level of 
CYR61 was in compliance with a mutated p53 gene and thus it seemingly replaced the function 
of p53. Besides prostate cancer, CYR61 has shown tumor suppressor properties in lung cancer, 
hepatocellular carcinoma, endometrial adenocarcinoma and melanoma. Collectedly seen, this 
protein urges for more exploration and it is guessed that it may serve as a biomarker for certain 
cancers25. 
 
Bcl-2  
Apoptosis is a vital ability to e.g. perform controlled regulation of embryogenesis as well as 
maintenance of tissue homeostasis. Apoptosis is accomplished through either an intrinsic or 
extrinsic pathway, where the intrinsic pathway is regulated by the Bcl-2 family and the extrinsic 
through members of the tumor necrosis factor (TNF) transmembrane “death receptors”26, see 
figure 5. 
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The Bcl-2 family comprises of both pro-apoptotic proteins, e.g. Bcl-10, Bax, Bak, Bid, Bad, Bim, 
Bik, and Blk, and anti-apoptotic proteins, e.g. Bcl-2, Bcl-x, Bcl-XL, Bcl-XS, Bcl-w and BAG, and they 
regulate each other in order to maintain homeostasis27. Ultimately, both pathways end up in an 
activation of the procaspases, which then, due to their proteolytic function, activates DNA 
nucleases that cleaves the DNA at specific sites, depending on the specific caspase27. 
 
FXR  
The nuclear transcriptional factor, Farnesoid X Receptor (FXR), is ample expressed in liver and 
intestine. Here it can be activated by up to 80 different compounds, with the major ligand being 
bile acid. Upon ligand binding, FXR moves to the nucleus, where it binds to DNA and either 
activate or repress gene transcription. It is shown to be involved in maintaining bile acid 
homeostasis through regulation of transport and synthesis of same. Furthermore, FXR is 
involved in repressing gluconeogenesis and lipogenesis, and research shows, that FXR is deficient 
in liver and intestine cancer28.  
 
 
 
 
 
Figure 5 Overview of intrinsic and extrinsic pathway for 
caspase-induced apoptosis. BH3 encompasses the pro-
apoptotic Bik, Bad, Bid, Bim, Bmf, Hrk, Noxa and Puma. 
Apaf-1 is shortened for apoptotic protease-activating factor 
1. tBid is yet another pro-apoptotic gene, which illustrates 
there may be cross-talk between the two pathways
26
.    
15 
 
ERK1/2 signaling pathway  
The extracellular signal-regulated protein kinase (ERK1/2), c-jun-amino-terminal kinase (JNK), 
p38 and ERK5, is all subfamilies in the mitogen activated protein kinase (MAPK) superfamily, 
which is involved in a multitude of functions, e.g. proliferation and survival29. The MAPK pathway 
is thought to be a factor in the development of cancer. A malfunctioning protein in the MAPK 
pathway can cause the pathway to stimulate cell division in an uncontrolled manner, leading to 
tumor development. Focusing in on ERK1/2, the pathway is depicted in figure 6, and the 
activation occurs through a cascade of upstream kinases. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 MAPK/ERK1/2 signal pathway.  Mitogens activate 
receptor tyrosine kinase (RTK), which then intracellular 
recruits the adaptor protein Growth factor receptor bound 
protein (Grb2) and SOS (son of sevenless). SOS now activates 
Ras through phosphorylation, and Ras can now recruit and 
activate Raf through phosphorylation. Raf further phos-
phorylates MEK1/2, enabling MEK1/2 to phosphorylate 
ERK1/2. Activated ERK1/2 phosphorylates RSK, and they both 
moves to the nucleus, where they activate transcription 
factors and ultimately leads to transcription of proteins 
involved in e.g. proliferation and cell survival
29
. 
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PI3K/Akt signaling pathway 
One of the suggested pathways for carcinogenesis is believed to be through activation of the 
phosphatidylinositol 3'-kinase (PI3K)-Akt pathway30, see figure 7. When growth factors stimulate 
the tyrosine kinase receptor, it is autophosphorylated and PI3K is recruited to the inner cell 
membrane and activated through binding with the receptor. PI3K can now convert PIP2 
(Phosphatidylinositol 4,5-bisphosphate) to PIP3 (phosphatidylinositol-3,4,5-trisphosphate). 
Subsequently, PIP3 and Phosphoinositide-dependent kinase-1 (PDK1) phosphorylates and 
activates Akt, which now can modulate functions of numerous substrates involved in regulation 
of cell cycle, cell cycle progression, cellular growth and inhibition of apoptosis31.  A key 
regulation point for this signaling pathway is at PTEN (phosphatase and tensin homologue), 
which is a PIP3 phosfatase, and thus can convert PIP3 back to PIP231. In cancer, the PI3K/Akt 
pathway is often highly activated30 and PTEN is suppressed through phosphorylation32.  
 
 
 
 
 
 
 
 
 
 
 
  
Figure 7 PI3K/Akt signal pathway. Growth factors 
phosphorylate PI3K which then converts PIP2 to PIP3 
and PIP3 further phosphorylates Akt. PTEN can re-
convert PIP3 to PIP2 (Own production). 
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NDRG2: Expression, functions and regulation in cancer  
 
Berit Juul Aarre and Sascha Andersen 
 
N-Myc downstream-regulated gene 2 (NDRG2) has been of interest in cancer the last decade, 
because a connection between NDRG2 expression level and the ability to be a tumor suppressor 
has been observed. More and more evidence is accumulating to acknowledge NDRG2 as a tumor 
suppressor and as a novel biomarker, but it isn’t fully established yet, and it is not yet clear how 
NDRG2 functions in various cancers and how it is regulated. Because this is a relative new 
research area, only few reviews are published. To attempt to fill this gap, this review summarizes 
literature from 2010 till present.  In the attempt to gain an overview of the knowledge of 
NDRG2, it starts by summarizing NDRG2 expression and its role as a tumor suppressor, a novel 
biomarker and its role in overall survival. NDRG2 has many functions in different cancers and this 
too will be described. Lastly NDRG2 can be regulated in different ways and this is included in the 
review. 
 
The NDRG family is comprised of NDRG1, 
NDRG2, NDRG3 and NDRG4 and is strongly 
conserved in plants, invertebrates, and 
mammals. This suggests that this gene 
family has important functions1,2, but since 
they have distinct expression patterns, it 
points towards that they have related and 
different functions in different tissues and 
organs2. The NDRG family all contributes to 
cell proliferation, differentiation, develop-
ment, and stress responses. NDRG2 is 
thought to specifically inhibit, through 
different pathways, proliferation, invasion 
and metastasis3.  
The scope of the present review is NDRG2 
and its role in cancer. NDRG2 is highly 
expressed in brain, heart, skeletal muscle, 
spinal cord and salivary gland1,2, but it has 
been described that both NDRG2 mRNA and 
protein is significantly downregulated in 
many different cancers. While Melotte and 
colleagues in 2010 had six different cancer 
included, this present review comprises 17 
different kinds of cancers. In 2010, NDRG2 
had been identified as a prognostic marker 
in gastric cancer3, but as this review shows 
it is no longer the case. Data for this review 
is collected through experiments in cell 
lines, human tissues specimens and in vivo 
experiments in mice, see table S1 for 
details.  
The review is designed to first give an 
overview of the expression status of NDRG2 
in 16 different cancers from 31 different 
studies and to give an update on the 
functions of NDRG2. Lastly it describes the 
newest gained knowledge on how NDRG2 is 
regulated. Three databases were used to 
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find articles from 2010 and till today: 
Google Scholar, SUMMON and Web of 
Knowledge. The search was done in 
February 2014 and 35 articles were found 
with NDRG2 and cancer as keywords.  
NDRG2 is denoted as a tumor suppressor in 
cancer3, but the mechanism underlying this 
has not yet been fully elucidated4. 
 
Expression of NDRG2 in cancer 
Roughly stated, carcinogenesis is when 
oncogenes have overruled TS-genes. The TS-
genes are often suppressed or mutated in 
malignant tumors, thereby heightening the 
possibility to proliferate despite of 
mutations. The research community has 
talked about NDRG2 as a new tumor 
suppressor gene for some time and the 
evidence of tumor suppressor charac-
teristics seems to be based on expression 
and altered functionalities5-7. In the 31 
studies of expression in cancer, which this 
review has investigated, NDRG2 is found to 
be downregulated in: ovarian cancer (Aarre 
& Andersen 2014 unpublished data), 
esophageal squamous cell carcinoma8,9, 
gastric cancer5, colorectal cancer6,10,11, oral 
squamous-cell carcinoma12, astrocytomas13, 
lung cancers14,15, glioma7, kidney cancer16-18, 
breast cancer19-22, papillary thyroid 
carcinoma19,23, gallbladder carcinoma24, 
pancreatic cancer25, prostate26,27, 
neuroblastoma28, Adult T-cell Leukemia-
Lymphoma (ATLL)29, bladder cancer30 and 
liver cancer31-33, see table 1 to gain a fluent 
impression of the diverse interconnections. 
The results shows no difference between 
whether NDRG2 mRNA or NDRG2 protein 
has been found to be of low expression and 
despite the uncertainty of whether mRNA 
will be translated into protein, the general 
assumption is that cells rarely transcribe 
without following translation. 
The same holds true when looking at 
NDRG2 in cell lines vs. tissue, where several 
studies shows a significant down-
regulation6,8,14. It should however be 
noticed that the spread in size of samples 
varies greatly and therefore additional 
studies should be applied, as e.g. goes for 
the unpublished data by Aarre and 
Andersen, 2014. 
Cancer is regularly divided up into clinico-
pathological features based on severity of 
the cancer and this is used to give a 
prognosis. In two of the commonly used 
features, TNM and differentiation grade, 
there are shown an inverse correlation 
between NDRG2 expression level and TNM 
stage and a positive correlation between 
NDRG2 and differentiation grade, which in 
some cases is called histological grade. TNM 
stage is a system based on T – the primary 
tumors size, N – if it has spread to the 
lymph nodes nearby and M – if there is any 
metastasis, and the cancers severity is 
categorized in five TNM stages ranging 
between 0-IV (National Cancer Institute). 
Well differentiated tumors tend to have a 
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slower growth and spreading rate compared 
to poor differentiated (National Cancer 
Institute). Based on this review, the 
tendency is that when NDRG2 expression 
level is low, the TNM grade will be high and 
well differentiated tumors will have higher 
NDRG2 expression levels 6-9,11,15,16,22,24,31.  
In one study of pancreatic cancer didn’t find 
any relationship between NDRG2 and 
clinico-pathological features and this can be 
due to sample size or the kind of cancer25. 
In the case of astrocytomas and glioma, the 
clinicopathological feature called the 
Karnofsky Performance scores (kps), which 
show how well cancer patient do ordinary 
tasks (National Cancer Institute), was 
correlated with NDRG2 level7,13. 
A cell-to-cell interaction molecule, CD24, is 
often dysregulated in connection to cancer. 
It is shown to be important in the quest to 
find the relationship between cancer and 
NDRG2, because this too has shown an 
inverse correlation with NDRG2 in 
gallbladder carcinoma and lung adeno-
carcinoma15,24.  
Even though not all cancer shows the same 
relationships to NDRG2, a clear picture is 
starting to emerge: NDRG2 has the 
expression pattern expected of a TS-gene. 
 
 
 
 
Table 1 A comprised schematic overview of data collected 2010-2014 of regulation of NDRG2 and NDRG2s diverse 
regulation in various cancers. The majority of functions and influenced pathways are observed after overexpression or 
knockdown of NDRG2. For more details, see table S1 (Own production). 
Cancer 
 
Expression 
level 
 
Regulation of 
NDRG2 
Functions 
Signaling 
pathway 
Source 
Brain 
 
Downregulated 
Induced by 
Oxygen-
Glucose 
Deprivation 
(OGD) 
Induces 
apoptosis 
and 
inhibits 
proliferation 
 
Upregulates Bax, 
p21, p27, Rsu1 
and smurf1 
Downregulates 
CDK4, cyclinD1 
and CYR61 
 
(7) 
(13) 
(28)  
(35) 
Kidney 
Downregulated 
or 
expressed in 
various levels 
Induced by 
p53 
 
Induces 
apoptosis 
and 
decreases 
proliferation, 
invasion, 
migration 
and 
level of EMT 
 
Upregulates 
PTEN, E-cadherin 
and VHL 
Downregulates 
HIF-1⍺, VEGF,  
cyclinD1, cyclinE, 
ẞ-catenin and 
EMT-related 
genes (snail, slug, 
Sip1) 
(16) 
(17) 
(18) 
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Cancer 
 
Expression 
level 
 
Regulation of 
NDRG2 
Functions 
Signaling 
pathway 
Source 
Colorectal Downregulated 
Indirectly 
induced by  
TGF-ẞ 
Downregulate
d by c-Myc,  
promotor  
hyper-
methylation 
and miR-650 
Decreases 
invasion, 
migration 
and tumor 
progression 
Attenuates TGF-ẞ 
induced EMT 
 
(6) 
(10) 
(11) 
 
Liver Downregulated 
Induced by 
FXR and 
hyperthermia 
45oC 
Induces 
apoptosis 
and 
decreases 
tumor 
growth, 
migration, 
invasion and 
metastasis 
Attenuate ERCC6 
and 
downregulates 
MMP-2, MMP-9, 
ERK1/2 and CD24 
(31) 
(32)  
(33)  
(36)   
(37) 
Prostate Downregulated 
Inhibited by  
c-Myc 
Increases 
apoptosis 
and 
decreases 
proliferation, 
growth, 
migration 
and invasion 
 
Upregulates p21 
Downregulates 
cyclinD1, CDK4, 
IL-8, MMP-2 and 
MMP-9 
 
(26) 
(27) 
Bladder Downregulated 
Inhibited by c-
Myc 
Decreases 
growth, 
migration 
and invasion 
 
Upregulates p21 
Downregulates 
CDK4, cyclinD1, 
MMP-2 and 
MMP-9 
(30) 
Gall-
bladder 
Downregulated 
 
 
 
Downregulates 
CD24 
(24) 
Pancreatic Downregulated 
Down-
regulated by 
histone 
modifications 
  (25) 
Breast Downregulated 
Inhibited by c-
Myc or is 
contradictory 
in a 
positive 
correlation 
with c-Myc 
Decreases 
tumor 
growth, 
invasion and 
metastasis as 
well as 
Inhibits 
angiogenesis 
 
Upregulates p53 
and VHL 
Downregulates 
active TGF-ẞ, HIF-
1⍺, VEGF and 
CD24 
(19) 
(20) 
(21) 
(22) 
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Cancer 
 
Expression 
level 
 
Regulation of 
NDRG2 
Functions 
Signaling 
pathway 
Source 
Cervical  
Induced by 
Cisplatin 
When 
NDRG2 is 
upregulated, 
it inhibits 
Cisplatin-
induced 
apoptosis 
Downregulation 
of NDRG2 
decreased Bcl-2 
level trough an 
upregulation of 
miR15b+miR16 
(38) 
Oral 
squamous 
cell 
Downregulated 
Down-
regulated by 
hyper- 
methylation 
 
Inhibits PI3K/Akt 
activation 
(12) 
Esopha-
geal 
squamous 
cell 
Downregulated 
Inhibited by  
c-Myc 
Increases 
apoptosis 
and 
decreases 
growth and 
proliferation 
 
Downregulates 
cyclinD1, Bcl-2 
and Ki67 
(8) 
(9) 
Lung Downregulated   
Downregulates 
CD24 
(14)  
(15) 
Thyroid Downregulated    
(19)  
(23) 
Gastric Downregulated 
Induced by 
hyperthermia 
and inhibited 
by hyper-
methylation 
 
Decreases 
invasion and 
apoptosis  
During 
hyperthermia, 
Akt 
phosphorylates 
NDRG2 
 
(5)  
(39) 
 
ATLL Downregulated 
Down-
regulated by 
methylation 
 
De-
phosphorylates 
PTEN 
(29) 
Ovarian Downregulated    
Aarre & 
Andersen 
un-
published 
data 
 
Biomarker  
A biomarker is used to detect, diagnose and 
predict a prognosis and select a suited 
treatment for the specific cancer. A 
biomarker is a molecule that can be located 
in either tissues or fluids including blood34 
(National Cancer Institute). NDRG2s low 
expression pattern in tumors makes it an 
ideal candidate as a biomarker and 
independent prognostic marker7,13-16,24,25. In 
line with the decreased level of NDRG2 
expression being a biomarker candidate, it 
is also relevant to find out if NDRG2 
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correlates with reduced survival. Overall 
survival rate is a statistical percentage and is 
used to make a prognosis, which can be 
translated to an estimated guess doctors 
makes for their patients on the basis of 
empirical data (National Cancer Institute). 
Out of the eight research groups who 
investigated overall survival rate and 
general overall survival, seven found that 
higher levels of NDRG2 gave better overall 
survival in patient with six different kinds of 
cancers: esophageal squamous cell 
carcinoma, colorectal cancer, astrocytomas, 
lung cancer, glioma and gallbladder 
carcinoma6-8,13-15,24, see table 2. Only one 
study in breast cancer, did not find any 
correlation between overall survival and the 
level of NDRG222. All agree that NDRG2 
expression level correlates with and affect 
prognosis and some state that NDRG2 
expression levels can be used for predicting 
prognosis and recurrence6,7,9,14,25. The 
inverse correlation between NDRG2 and 
CD24 has been found to be related to 
prognosis as well15,24. 
 
Table 2 Extracted data of overall survival and 5-year survival rate of 6 different cancers. Overall survival is measured in 
month and 5-year survival rate is measured in percent (Own production). 
 Overall survival [month] 5-year survival rate [%]  
Cancer  Patients All 
patients  
High 
NDRG2 
Low 
NDRG2 
All 
patients  
High 
NDRG2 
Low 
NDRG2 
Source  
Esophageal 
squamous 
cell 
carcinoma  
143  39 19  36.1 6.7 (8) 
Colorectal 
cancer 
226 38 
 
54 35    (6) 
Astro-
cytomas  
41  39a 10a  >70d <40d (13) 
Lung cancer 185  Betterb Lowerb 37.8   (14) 
Glioma 316 15 All sur-
vived 
10-16c   Lower (7) 
Gallbladder 
carcinoma  
130     53.06 24.69 (24) 
Lung adeno-
carcinoma 
166     Betterb,
e 
Lowerb,
e 
(15) 
a 157 weeks and 41 weeks respectively.  
b Significant  
c Weak positive and negative expression, 
respectively.  
d 3-year survival rate  
e Together with CD24 
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Functions  
In the path of carcinogenesis, there are 
certain hallmarks that, besides a high 
proliferation rate and attenuated apoptosis, 
includes the epithelial-mesenchymal 
transition (EMT) and thus a high invasion 
profile, which needs to be achieved in the 
cells path to become malign40,41.  
It is of growing interest to investigate 
NDRG2s regulating role in the multiple 
signaling pathways leading to the above 
functions. To gain a quick overview of the 
multiple signaling pathways and functions 
NDRG2 has shown to be implicated in, see 
figure 1. 
 
 
 
Proliferation and apoptosis 
A cells cycle consist of the 5 stages: G0, G1, 
S, G2 and M, with G0 being the dormant 
stage. One of the major checkpoints is when 
cells are to enter S-phase, and this is tightly 
regulated by cyclins and cyclin dependent 
kinases (CDK). Research reports have shown 
that an overexpression of NDRG2 in 
neuroblastoma, bladder, renal and prostate 
cancer cell lines all resulted in a reduction of 
cyclinD1 and CDK4 and thus a cell cycle 
arrest at G1 phase18,26,28,30. In esophageal 
Figure 1 Overall figure showing regulation of NDRG2 and NDRG2s involvement in signaling 
pathways and functions (Own production). 
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squamous cell carcinoma there has also 
been shown a connection between 
overexpression of NDRG2 and down-
regulation of cyclinD1 and the anti-
apoptotic Bcl-2 protein, which likewise gave 
a cell cycle arrest at G1 phase and 
attenuated proliferation and tumorgenesis9. 
Similar results were found in mice, where 
Cao and colleagues injected Eca-109 
adenovirus-NDRG2 cells into preexisting 
tumors consisting of Eca-109 cells and after 
24 days saw a low expression of cyclinD1 
and ki67 which resulted in a significant hold 
of tumor growth8. 
Two main regulators for the complex 
cyclin/CDK4/6 are p21 and p27 and due to 
overexpressed NDRG2, an upregulation of 
both were detected simultaneous with 
reduced cyclin and CDK426,28 and Li and 
colleagues obtained similar results, but 
without  p2730. Ma and colleagues saw a 
downregulation of cyclinE, indicating that 
NDRG2 can be involved in both early stage 
and late stage of the G1 phase18. The 
controlling of the expression of p21 is a key 
regulation mechanism when it comes to 
whether a cell commits to mitosis or not, 
and it is established that Transforming 
Growth Factor-Beta (TGF-ẞ) is such a 
regulator for the expression of p2142. 
Concerning TGF-ẞ, its involvement in 
carcinogenesis can be characterized as both 
a TS-gene in the early onset of cancer and as 
an oncogene in the late stages43. According 
to this, Oh and colleagues found that highly 
expressed NDRG2 in breast cancer 
suppressed metastasis through an 
attenuation of the expression of active TGF-
ẞ and suspects that this is accomplished 
through downregulation of integrin ẞ6, but 
further elucidation is needed22. In context of 
controlling whether the cell should 
commence full cell cycle, the regulation for 
expressed p21, is besides TGF-ẞ, similarly 
been established to be partly controlled by 
p5344,45. This versatile protein is a pivotal 
agent in determining whether apoptosis 
should be initiated. Cao and colleagues 
found that an overexpression of NDRG2 in 
cancerous liver cells led to enhanced p53-
mediated apoptosis through a down-
regulation of expressed ERC66, which is a 
protein involved in nucleotid excision repair 
mechanism37. Apoptosis was similar shown 
to be heightened when astrocytes were 
treated with glucose and oxygen 
deprivation, and this upregulated NDRG2 
and promoted an upregulation of the pro-
apoptotic gene Bax35.  
Contradictory to the general notion that an 
upregulation of NDRG2 is desirable, Liu and 
colleagues showed that the heightened 
level of NDRG2 diminished the drug 
Cisplatin ability to induce apoptosis38. 
Moreover, NDRG2 has in two independent 
studies shown to regulate the activation of 
PI3K/Akt signaling pathway, which is 
reported to regulate progression of cell 
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cycle, growth and induction of apoptosis. 
While Furuta and colleagues found that 
NDRG2 inhibits phosphorylation of Akt at 
Ser473 in oral squamous cell carcinoma, 
Nakahata and colleagues investigated the 
cancer ATLL and found that NDRG2 recruits 
protein phosphatase 2A (PP2A), which then 
dephosphorylates PTEN and thus enables 
PTEN to convert PIP3 back to PIP212,29. 
Nakahata and colleagues also showed that 
there is an inverse correlation between 
NDRG2 and phosphorylation of Akt Ser473 
for oral squamous cell cancer. Lastly they 
showed that low levels of NDRG2 in 
pancreatic, ovarian, cervical and oral 
squamous cell carcinoma corresponded to 
high levels of phosphorylated PTEN and Akt 
Ser473, which indicates a similar pathway 
regulation for NDRG2 in numerous cancer 
types. 
As a tumor proliferates, it reaches a 
threshold for adequate blood supply, and 
the diminished levels of O2 inhibits the 
degradation of hypoxia-inducible factor1-⍺ 
(HIF-1⍺) through complex formation with 
VHL (von Hippel-Lindau). The elevated level 
of HIF-1⍺ induces transcription of Vascular 
Endothelial Growth Factor (VEGF), which is 
a key regulator for e.g. formation of 
angiogenesis46. In 2012 researchers found 
that NDRG2 overexpressed in breast cancer 
could downregulate VEGF and HIF-1⍺ 
through an upregulation of p53 and the TS-
gene VHL and this were shown to give an 
arrest in formation of angiogenesis and thus 
tumor growth20. Similar pathway were 
found to be influenced by NDRG2  in renal 
cells, where they saw an hindrance of 
proliferation, migration and invasion and 
they advise more research to elucidate the 
exact regulation17.  
Lastly NDRG2 has been seen to down-
regulate CYR61 in neuroblastoma, and a 
following attenuation of proliferation28.   
 
Migration, invasion and metastasis 
Cancerous cells reach a final stage when 
they gain the ability to migrate and thereby 
become invasive to tissues located 
periphery to the primary tumor. Several 
proteins are involved in adhesion and cell-
to-cell interactions, one of them being 
CD24. In breast and liver cancer cell lines 
and in gallbladder carcinoma as well as lung 
adenocarcinoma tissue, an inverse 
correlation was found between over-
expressed NDRG2 and diminished CD24 and 
thus a decrease in the cells ability to 
migrate and become invasive15,21,24,31. 
Besides CD24, the metalloproteinases 
MMP-2 and MMP-9 are also involved in 
EMT through degradation of the ECM and 
basement membrane. MMP-2 and MMP-9 
enzymes are in bladder, prostate and liver 
cancer shown to be downregulated when 
an induced expression of NDRG2 is 
established, and thus results in a hindrance 
of invasion and metastasis27,30,36. Similarly in 
renal cancer, overexpressed NDRG2 
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resulted in inhibited migration through 
suppression of the EMT related genes snail, 
Slug, Sip1 and ẞ-catenin and an 
upregulation of E-cadherin and PTEN 
expression16. Lastly, in liver cancer cells, 
Guo and colleagues showed that induced 
NDRG2 resulted in a diminished 
phosphorylation of ERK1/2, which also 
attenuated the invasive ability36. 
When highly proliferating cancerous cells 
gain migratory properties and penetrate 
into lymph or blood vessels, there is a high 
probability they will metastasize elsewhere 
in the body. There are for some cancer 
forms specific places one can expect to 
locate secondary tumor development, like 
in the case of prostate cancer, where the 
cancer usually spreads to the bones. 
Researching into minimizing the ability for 
cancer to cause bone decay and thereby 
causing secondary illness is therefore of 
interest, and NDRG2 has proven to inhibit 
interleukin-8, an important factor in bone 
destruction27.  
 
Regulation of NDRG2 
It is stated in this review that NDRG2 is 
downregulated in various cancers and that 
NDRG2 have different functions in these 
cancers, but how is NDRG2 regulated? 
NDRG2 is shown to be regulated 
endogenous by c-Myc9,26,30, TGF-β11, FXR 
and bile acids32,33, p5318,35 and 
hypermethylation5,10,12, and can also be 
regulated externally by stress36,39.  
As the name N-Myc downstream-regulated 
gene 2 applies, it has a close relationship to 
the Myc-family and especially c-Myc. The 
relationship seems to be that c-Myc 
transcriptional represses NDRG2 and 
therefore c-Myc and NDRG2 protein have 
an inverse correlation9,26,30. However, one 
study has found a weak positive correlation 
between c-Myc and NDRG219.   
A study in colorectal cancer additionally 
shows that a downregulation through c-Myc 
is partly abrogated by TGF-ẞ through the 
termination of the interaction of c-Myc and 
Miz-1, indicating an upregulating 
mechanism for NDRG2 by TGF-ẞ through 
regulation of c-Myc11.  
The fact that c-Myc plays a part in the 
regulation of NDRG2 is beginning to be 
clear, but how is still a question that needs 
to be elucidated.   
Furthermore, two independent research 
results have shown that FXR, a bile acid 
receptor located primarily in liver and 
kidney, gave rise to elevated levels of 
NDRG2 through a putative IR1 element, 5’-
GGGTTAGTGACCC-3’, when overexpressed. 
The interesting thing is that Deuschle and 
colleagues found this IR1 element in the 
first intron of both human and murine 
NDRG2 where Langhi and colleagues found 
it in the second intron of human NDRG2 and 
in the first intron of murine Ndrg2. More 
research is therefore needed to enlighten 
the details. When FXR were knocked down, 
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the expression of NDRG2 was reduced, so 
here they saw a positive correlation32,33.  
Epigenetics and hereunder hyper-
methylation is a new and growing part in 
understanding carcinogenesis and has 
therefore been a subject for investigation in 
the quest to find a possible regulator of 
NDRG2. From 2010, five different studies in 
four different cancers: oral squamous cell 
carcinoma, colorectal cancer, ATLL and 
gastric cancer, have found that 
hypermethylation is involved in the 
downregulation of NDRG25,10-12,29. Albeit 
another study has found that the 
downregulation of NDRG2 is mainly because 
of histone modification25. Additionally, Feng 
and colleagues showed that the microRNA 
miR-650 is a direct regulator of NDRG210.  
NDRG2 has been shown to be a stress 
responsive gene and that Oxygen-Glucose 
Deprivation (OGD) can upregulate NDRG2 in 
a time-dependent manner. The OGD is 
further associated with p53, because when 
p53 is silenced, then the upregulation of 
NDRG2 is suppressed35, which is in line with 
what Ma J.-J. found in 2010, that NDRG2 is 
p53-regulated18.  Hyperthermia is another 
good example of an external stressor for 
NDRG2. Hepatocellular carcinoma cells 
were subjected to hyperthermia at 45°C 
which induced NDRG236. Cisplatin, a drug 
used in many kinds of cancer, has shown 
stressor ability on NDRG2 by upregulating 
the protein in a time-dependent manner in 
Hela cells38. The differences in regulation 
can be based on the different tissues and 
cell lines, but also different etiology of 
different cancer forms can be important and 
therefore more studies are needed. 
 
Conclusions and future 
challenges  
This review clearly depicts that NDRG2 is to 
our knowledge downregulated in all cancer 
forms investigated since 2010, and focus 
has been on NDRG2s role in the different 
cancer forms as well as survival. They have 
shown that NDRG2 acts through several 
pathways. Some of the results show a 
regulation of a function through different 
pathways in different forms of cancer, while 
others show that the same pathway is 
regulated in different cancers and yielding 
both the same or different function. Due to 
that it is difficult to state something 
consistent about NDRG2s role in cancer, 
hence this review suggest that more 
research is needed to both independently 
validate these results and to more fully 
elucidate NDRG2s role. This is further 
supported by Liu X. and colleagues, who 
have shown that NDRG2 upregulates 23 
genes and downregulates 235 genes in liver 
cells, illustrating the complex network 
NDRG2 is implicated in4.  
A lack of a universal biomarker for cancer is 
not surprising, when considering tumor-
genesis is a complicated process where 
several genes are involved13. Nevertheless 
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NDRG2 might be the exception.  Its 
consistently low expression in various 
cancers, as shown in this review, indicates 
NDRG2 might just be the universal 
biomarker researchers have been looking 
for. In 10 different studies of eight cancer 
forms NDRG2 have been proclaimed to be a 
new marker for the examined cancer and in 
six of these cancers NDRG2 is stated to be 
an independent prognostic factor6-9,13-16,24,25. 
In addition, in two of the cases NDRG2 were 
found in co-expression with CD24 when 
considered to be an independent prognostic 
factor15,24.  
All, but one of the articles investigating 
NDRG2 as an independent prognostic factor 
have found that low NDRG2 level can be an 
indicator for shorter survival6,7,15,16,24,25. It is 
however proclaimed that due to the limited 
current research in selected cancer types, 
more research is imperative to gain a better 
picture. 
In closing, the compilation of data indicates 
possibilities in the use of regulation of 
NDRG2 in cancer treatment and prognosis, 
and may in the future serve as a novel 
treatment for several cancer forms. 
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Supplementary data  
Table S1 A schematic overview of 35 articles and their findings of NDRG2 involvement in cancer. Majority of functions is achieved by overexpressing or knockdown of NDRG2. Pt. is short for 
patients. Expression level is obtained by comparing cancerous cells/tissue with non-cancerous cells/tissue (Own production). 
 
Cancer 
 
Test medium Expression level Regulation of NDRG2  Functions Signaling pathway Source 
Astrocytoma Tissue (63 pt.) Downregulated    (13) 
Glioma 
Tissue (316 
pt.) 
Downregulated    (7) 
Astrocyte 
Primary 
cells 
 
Upregulated by Oxygen-
Glucose Deprivation 
(OGD) 
 
Induces apoptosis Upregulates Bax (35) 
Neuroblastoma 
SK-N-SH 
SH-SY5Y 
Downregulated  
Inhibits 
proliferation 
Upregulates 
p21/p27/Rsu1/smurf1 
Downregulates 
CDK4/cyclinD1/CYR61 
 
(28) 
Kidney A-498 Downregulated Upregulated by p53 
Inhibits 
proliferation 
Induce apoptosis 
Decreases cyclinD1 and 
cyclinE 
(18) 
Kidney 
786-O 
A-498 
Mice 
Tissue (130 
pt.) 
Downregulated  
Inhibits 
proliferation, 
invasion and 
migration 
Increases VHL and 
Decreases HIF-1⍺, VEGF 
(17) 
Kidney 
SN12C 
786-O 
ACHN 
Tissue (112 
pt.) 
Expressed in various 
levels 
 
Decreases EMT and 
migration 
Upregulates E-cadherin and 
PTEN, 
Decrease ẞ-catenin and EMT-
related genes ( snail, slug, 
sip1) 
(16) 
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Cancer 
 
Test medium Expression level Regulation of NDRG2  Functions Signaling pathway Source 
Colorectal 
HT29 
HCT116 
SW480 
SW620 
CaCo2 
Tissue (50 pt.) 
Downregulated 
TGF-ẞ can induce NDRG2 
trough upregulation of 
Sp1 and downregulation 
of c-Myc/Miz-1 
-- 
Downregulated by 
Hypermethylation 
Decreases invasion, 
migration and 
tumor progression 
Attenuates TGF-ẞ induced 
EMT 
(11) 
Colorectal 
Tissue (226 
pt.) 
Downregulated    (6) 
Colorectal 
SW480 
HT29 
SW620 
LOVO 
Tissue (70 pt.) 
Downregulated 
Downloaded by 
promoter 
hypermethylation 
-- 
Downregulated by  
miR-650 
  (10) 
Liver 
HepG2 
Huh7 
Mice 
  
Induces apoptosis 
and decreases 
tumor growth 
Attenuates ERCC6 (37) 
Liver 
HepG2 
Huh7 
Mice 
Downregulated 
Induced by bile acid 
activation of FXR 
through binding to IR1 
element 
Reduces tumor 
growth and 
metastasis 
 
(32) 
(33) 
Liver 
HepG2 
Huh7 
Mice 
 
Induced by 
hyperthermia 45oC 
Decreases invasion 
Inhibits MMP-2, MMP-9 and 
ERK1/2 
(36) 
Liver 
Huh7 
MHCC97H 
Tissue (50 pt.) 
Downregulated  
Decreases 
migration and 
invasion 
Inhibits CD24 (31) 
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Cancer 
 
Test medium Expression level Regulation of NDRG2  Functions Signaling pathway Source 
Prostate 
PC3 
LNCaP 
DU145 
Mice 
Tissue (144 
pt.) 
Downregulated Downregulated by c-Myc 
Decreases growth 
and increases 
apoptosis 
Increases p21 and inhibits 
cyclinD1, CDK4 
(26) 
Prostate 
PC3 
DU145 
Mice 
Downregulated  
Inhibits 
proliferation, 
migration, invasion 
and metastasis 
Inhibits IL-8, MMP-2 and 
MMP-9 
(27) 
Bladder 
T24 
5637 
BIU-87 
Mice 
Tissue (112 
pt.) 
Downregulated 
Downregulated by        
 c-Myc 
Decreases growth, 
migration and 
invasion 
Upregulates p21 and 
downregulates CDK4, 
cyclinD1, MMP-2, MMP-9 
 
(30) 
Pancreatic 
PANC-1,  
PK-1, 
PCI-35,  
BxPC-3, 
PK-45P, PK9, 
MIAPaCA-2, 
AsPC-1, PK8 
Tissue (69 pt.) 
Downregulated 
Downregulated by 
histone modifications 
  (25) 
Breast 
4T1 
Tissue (189 
pt.) 
Downregulated  
Decreases tumor 
growth, invasion 
and metastasis 
 
Decrease active TGF-ẞ 
through decrease of integrin-
beta6 
(22) 
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Cancer 
 
Test medium Expression level Regulation of NDRG2  Functions Signaling pathway Source 
Breast 
MCF-7 
Mice 
Downregulated  
Inhibits 
angiogenesis and 
growth 
Increases p53, VHL and 
Decreases HIF-1⍺, VEGF 
(20) 
Breast 
 
MCF-7 
Bcap-37 
 
Downregulated  Decreases invasion Downregulates CD24 (21) 
Breast Tissue (4 pt.) Downregulated 
Positive correlation with 
c-Myc 
  (19) 
Cervical Hela  Upregulated by Cisplatin 
 
Inhibition of 
NDRG2 enhanced 
Cisplatin-induced 
apoptosis 
 
Downregulated NDRG2 
inhibited Bcl-2 trough 
upregulation of miR-15b + 
miR-16 
(38) 
Oral squamous 
cell 
HSC2/3/4, 
SAS, HO-1-u-
1, HSQ-89, 
Ca9-22, Sa-3 
Tissue (64pt.) 
Downregulated 
Downregulated by hyper 
methylation 
Decreases 
proliferation and 
growth 
 
Inhibits phosphorylation and 
thus activation of PI3K/Akt 
(12) 
 
Esophageal 
squamous cell 
EC8717, 
KYSE30, 
KYSE70, 
KYSE150, 
Eca-109 
Mice 
Tissue (143 
pt.) 
 
Downregulated 
 
 
Inhibits growth and 
proliferation 
 
Downregulates cyclinD1 and 
Ki67 
 
(8) 
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Cancer 
 
Test medium Expression level Regulation of NDRG2  Functions Signaling pathway Source 
Esophageal 
squamous cell 
EC9706, 
EC109, 
EC8712, 
KYSE150, 
KYSE70, 
KYSE510 
Mice 
Tissue (154 
pt.) 
Downregulated 
Downregulated by        
 c-Myc 
Decreases growth, 
proliferation and 
Increases apoptosis 
Downregulates cyclinD1 and 
Bcl-2 
(9) 
Gall bladder 
 
Tissue (130 
pt.) 
 
Downregulated   Inhibits CD24 (24) 
Lung 
Tissue (185 
pt.) 
Downregulated    (14) 
Lung 
 
Tissue (166 
pt.) 
 
Downregulated   Downregulates CD24 (15) 
Thyroid Tissue (7 pt.) Downregulated    (19) 
Thyroid Tissue (16 pt.) 
Downregulated and 
same level in 
primary tumor as in 
metastasis 
   (23) 
Gastric 
MKN45 
MKN28 
 
Phosphorylated after 
Hyperthermia (42oC) 
Decrease of 
induced apoptosis 
when 
phosphorylated 
PI3K/Akt phosphorylate 
NDRG2 at Ser332 and Thr348 
(39) 
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Cancer 
 
Test medium Expression level Regulation of NDRG2  Functions Signaling pathway Source 
Gastric 
HGC27, AGS, 
MKN45, 
SGC7901, 
BGC823, 
MGC803, 
Tissue (42 pt.) 
Downregulated 
Downregulated by 
hypermethylation 
Decreases invasion  (5) 
ATLL 
MT2, KOB, 
MOLT4 
Downregulated 
Downregulated through 
methylated promoter 
region 
 
Overexpressed NDRG2 
recruits PP2A, which de- 
phosphorylates PTEN at 
Ser380/Thr382/Thr383 
(29) 
Ovarian 
SKOV-3 
Tissue (6 pt.) 
Downregulated    
Aarre & 
Andersen, 
Unpublished 
data 
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Quantitative analysis of NDRG2 expression in ovarian tissue and NDRG2 
Alternative Splice Forms in Ovarian Cancer 
 
Berit Juul Aarre and Sascha Andersen 
 
Background: NDRG2 has been of interest in the last decade in various cancers forms, because a connection 
between NDRG2 expression level and the ability to be a tumor suppressor has been observed. Ovarian 
cancer has been somewhat overlooked in this context. This preliminary study has NDRG2 expression level 
in ovarian cancer in focus. NDRG2 has been observed to have two isoforms and to our knowledge this is the 
first study examining the difference in expression of the alternative splice forms of NDRG2.  
Method: In this study real-time PCR was used to detect the expression level of NDRG2 in the ovarian cell 
line SKOV-3 and in ovarian cancerous tissue compared to normal ovarian tissue. The Comparative Ct 
Method was used to calculate the relative expression level compared to the liver positive control. Normal 
PCR and agarose gel was used to check for alternative NDRG2 splice forms in the ovarian cell line SKOV-3 
and in ovarian cancerous tissue.  
Results: It was found that NDRG2 mRNA is downregulated in both the ovarian cell line SKOV-3 and in the 
ovarian cancerous tissue compared to the normal ovarian tissue. Both alternative slice forms of NDRG2 are 
present in both the ovarian cancer cell line SKOV-3 and in the ovarian cancerous tissue as well as in the 
normal ovarian tissue, and there are indications of variable interrelations in some of the samples and 
between the samples. 
Conclusion: The data suggest that NDRG2 is downregulated in ovarian cancer and that the two alternative 
splice forms of NDRG2 mRNA are present in ovarian tissues, and therefore more research is advised.  
Keywords: NDRG2, ovarian cancer, isoforms, alternative splice forms 
 
Ovarian cancer is the fifth most common cause of 
death by cancer in women (National Cancer 
Institute) and the 11th most common cancer in 
women (Ovarian Cancer National Alliance). In the 
United States there are an estimated 21,980 new 
cases in 2014 and an estimated 14,270 numbers 
of deaths (National Cancer Institute). In all cases 
of ovarian cancer, 50 % is women over the age of 
65 (National Cancer Institute).   
NDRG2 is part of the NDRG family, which is 
comprised of four members; NDRG1, NDRG2, 
NDRG3 and NDRG4. All four members of the 
NDRG family show an amino acid identity of 57–
65 % to one another1. NDRG2 (GenBank number 
AF159092) is located at chromosome 14q11.21 
and the protein is comprised of 371 amino acids2 
or 357 amino acids, indicating two isoforms of 
the protein, with a molecular weight of 41kDa3.  
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The difference in amino acids is due to an 
alternative splicing of mRNA which omits 42 
nucleotides, but these have yet to come into 
focus. Moreover NDRG2 is a nonenzymatic 
member of the α/β hydrolase superfamily2.   
Ovarian cancer is the scope of this preliminary 
study because, to our knowledge, the only study 
that examines NDRG2 expression in ovarian 
cancer is the pre-study from Lorentzen and 
colleagues, which was inconclusive of the 
expression of NDRG2 in ovarian tissue4. Therefore 
this present study is looking into NDRG2 
expression in the cell line SKOV-3 and cancer 
tissue. Additional, this is, to our knowledge, the 
first to show the two alternative splice forms 
clearly expressed in ovarian cancer. 
 
Materials and Method  
Cell culture and tissue samples  
For the positive control of NDRG2 and the 
housekeeping gene, RPLP0, a standard curve was 
made for each with human liver cDNA from 
Human MTC panel I (Clontech). The dilution 
curves for the standards were: water, undiluted, 
5x, 25x, 125x, 625x and 3125x diluted in duplicate 
for both NDRG2 and RPLP0. The 25x diluted in 
human liver cDNA was chosen as the positive 
control for further studies.  
One normal ovarian tissue, ovarian cDNA from 
Human MTC Panel II, Clontech (catalog no. 
636743 and lot no. 1204481A) and one human 
ovarian carcinoma cell line SKOV-3 cDNA from 
Human Cell Line MTC Panel, Clontech (catalog no. 
636753 and lot no. 6090253) were obtained for 
the cell line study. For the tissue study one 
normal ovarian cDNA tissue sample and five 
cancers from Origene Starter kit were used, see 
table 1 for patient information. The cDNA from 
Clontech was diluted 10x and the cDNA from 
Origene was resuspended in 8µL H2O.  
 
Table 1 Patient information showing age, gender and clinicopathological features. E7-E12 are sample labels.  
 E7 E8 E9 E10 E11 E12 
Gender Female Female Female Female Female Female 
Age 54 58 91 49 47 68 
Appearance Normal Cancerous Cancerous Cancerous Cancerous Cancerous 
Tumor grade  Poorly 
differen- 
tiated 
Poorly 
differen- 
tiated 
Poorly 
differen-
tiated 
Borderline 
malig-
nancy 
Poorly 
differen-
tiated 
Poorly 
differen-
tiated 
Tumor stage 0  IIB III IIIA IIIC IV 
 
Real-Time PCR 
The real-time PCR amplification of NDRG2 and 
RPLP0 was performed with Agilent Technologies. 
The forward and reverse primers for NDRG2 were 
5’-GCTACAACAACCGCCGAGAC-3’ and  5’-
ACAGGCGAGTCATGCAGGAT-3’ respectively, 
yielding a product of 270bp. The forward and 
reverse primers for RPLP0 were 5’-
GCTTCCTGGAGGGTGTCC-3’ and 5’-
GGACTCGTTTGTACCCGTTG-3’ respectively, giving 
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a product of 110bp. Added to a master mix 
consisting of: 5µL Quantitect SYBR Green I PCR kit 
(QIAGEN #204141), 1µL forward primer, 1µL 
reverse primer and 2µL nuclease free water, was 
1µL of template to yield a total reaction volume 
of 10µL. The real-time PCR program used for 
NDRG2 was one cycle to initial enzyme activation 
at 95°C for 15 min, 45 cycles of denaturation at 
95°C for 15 sec, annealing at 55°C for 30 sec and 
elongation at 72°C for 30 sec and the melting 
temperature cycle was 95°C for 15 sec, 55°C for 
30 sec and 95°C for 30 sec. The real-time PCR 
program used for RPLP0 was 95°C for 15 min, 45 
cycles at 95°C for 15 sec, 52°C for 15 sec, 72°C for 
30 sec and the melting temperature cycle was 
95°C for 15 sec, 52°C for 30 sec and 95°C for 30 
sec.  
To analyze the mRNA expression of NDRG2 the 
Comparative Ct Method (2
-ΔΔCt) was used5.  
 
Traditional PCR 
The samples described in Cell culture and tissue 
samples are also used in the alternative splice 
form study. The PCR amplification of NDRG2 was 
performed with Biometra. The forward and 
reverse primer for NDRG2 were 5’-
CACCATGGCGGAGCTGCAGGAG-3’ and 5’-
AAGGGATCATGTCTGCAAGCTGGTC-3’, 
respectively and their PCR products were 390bp 
and 350bp, respectively for the two alternative 
NDRG2 splice forms. A master mix was created by 
mixing 66µL sterile water, 11µL of forward primer 
(10pmol/µL), 11µL of reverse primer (10pmol/µL) 
and 110µL Maxima Hot Start. In 4 tubes with 
18µL master mix was added 2µL of sterile water, 
25x diluted liver cDNA, 10x diluted ovarian tissue 
cDNA or 10x diluted SKOV-3 cDNA, respectively, 
for the first run. For the second run,  10 tubes 
with 18µL master mix was added 2µL of sterile 
water, 250x diluted human liver cDNA, 100x 
diluted human ovarian tissue cDNA, 10x diluted 
SKOV-3 cDNA, normal ovarian human tissue 
cDNA, (E7) and 5 different cDNA samples of 
cancerous cDNA (E8-E12), respectively. The PCR 
program used for the two runs only differ in the 
number of cycles, 30 and 35 respectively. First 
cycle; at 94°C for 4 min, five cycles; at 94°C for 30 
sec, at 68°C for 30 sec and at 72°C for 1 min, 
30/35 cycles; at 94°C for 30 sec, at 64°C for 30 
sec and at 72°C for 1 min, one cycle; at 72°C for 5 
min. Due to insufficient patient materials, we 
only had tissue cDNA for one gel and chose to 
amplify E7-E12 for 35 cycles.  
A gel was done for both runs. The gels were 
molded of 1.4g agarose and 100mL TBE 1x and 
added to this was 10µL Ethidium bromide. To the 
buffer in the gel tanks were added 10µL Ethidium 
bromide. 5µL loading buffer was added to all the 
samples. 12.5µL was placed in the wide wells in 
the gels of all the samples. The gels ran for 
approximately for 2 hours at 120V to ensure a 
good separation. The gene ruler used was 
GeneRulerTM 1 kb Plus DNA Ladder, ready-to-use 
from Fermentas, sm1333. 
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Results 
Standard curves 
To determine the relative expression level of 
NDRG2 in the ovarian cancer tissue samples, first 
a standard curve for NDRG2 and RPLP0 were 
performed in liver cDNA. The standard curves 
showed to be accurate because efficiency values 
were close to 100 % and the slopes were -3.32, 
see figure 1 and 2. The standard curves had 
several purposes. For both, it was to check the 
primer efficiency, for NDRG2 to find a positive 
reference control and lastly to check for 
consistency in the expression of RPLP0.  The Ct 
values of the standard curves were further used 
to validate RPLP0 as a proper choice of gene to 
use as a normalization of NDRG2 later in the 
study, see supplementary data for validation 
experiment. The positive control was chosen 
based on equal Ct values and the 25x diluted liver 
cDNA was hence found to be the calibrator. Due 
to SYBR Green I’s ability to bind to all dsDNA and 
thus creating a fluorescence background, a 
threshold was determined to be 0.145 and 0.07 
for NDRG2 and RPLP0, respectively, which gave 
nearly equal efficiency for both.  
 
 
Figure 1 Standard curve for NDRG2 expression in liver cDNA. 
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Expression in cell line 
The results are inconclusive because the negative 
control is contaminated. Therefore the result of 
SKOV-3 cannot be conclusive on whether it is a 
low expression of NDRG2 in the cancer cell line 
SKOV-3 or it is contamination, as in water, see 
table 2. Furthermore the high Ct value in SKOV-3 
states that the primary product consist in very 
small amounts, which further could indicate a 
contamination, albeit in other studies it is shown 
that NDRG2 is nearly absent in cancer6,7. Despite 
of this, the Comparative Ct Method indicates that 
there are a significant downregulation of NDRG2 
in the cancer cell line SKOV-3 compared to 
normal ovarian tissue (98.8 %) and compared to 
liver (99.4 %), see table 3. The study was 
replicated to correct the contamination, but 
failed.   
 
Table 2 Showing the Ct values for, the positive control, normal ovarian tissue, the SKOV-3 cell line and the negative control.  
Sample NDRG2 Re-run NDRG2 RPLP0 
Liver 25x 26.45 26.65 17.67 
26.52 26.89 18.33 
26.53 26.60 18.29 
Normal ovarian tissue 26.23 26.44 16.81 
26.00 26.29 17.06 
26.23 26.13 16.14 
SKOV-3 34.31 34.63 19.08 
35.07 35.84 19.05 
35.05 34.72 18.92 
NTC 37.19 34.29 32.15 
35.38 36.01 - 
34.86 34.69 44.32 
Figure 2 Standard curve for RPLP0 expression in liver cDNA. 
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Table 3 Showing the relative NDRG2 expression compared to liver, for all test samples: positive control, normal ovarian tissue, 
SKOV-3 and E7-E12.  
Tissue NDRG2 
average Ct 
RPLP0 average 
Ct 
ΔCt (NDRG2-
RPLP0) 
ΔΔCt (ΔCt-ΔCt 
Liver) 
NDRG2 relative 
to liver (2-∆∆Ct) 
Liver 25x 26.50 ±0.044 18.10 ±0.37 8.40 0.00 1.0000 
Normal 
ovarian tissue 
26.15 ±0.133 16.67 ±0.48 9.48 1.08 0.4730 
SKOV-3 34.81 ±0.433 19.92 ±0.09 15.79 7.39 ≤0.0060 
      
Re-run liver 
25x 
26.71 ±0.155  8.62 0.00 1.0000 
Re-Run normal 
ovarian tissue 
26.29 ±0.155  9.62 1.00 0.5000 
Re-run SKOV-3 35.06 ±0.674  16.05 7.43 ≤0.0058 
      
Liver 25x 26.70 ±0.106 19.13 ±0.14 7.57 0.00 1.0000 
E7 30.07 ±0.278 18.93 ±0.61 11.14 3.57 0.0842 
E8 34.72 ±0.112 19.22 ±0.11 15.51 7.94 ≤0.0041 
E9 33.98 ±0.710 20.49 ±0.17 13.48 5.91 ≤0.0166 
E10 34.43 ±0.681 20.08 ±0.61 14.34 6.77 ≤0.0091 
E11 33.56 ±0.298 20.28 ±0.20 13.28 5.71 ≤0.0191 
E12 32.78 ±0.638 17.83 ±0.47 14.95 7.38 ≤0.0060 
 
Expression in tissue  
As in the cell line, the negative control showed a 
fluorescent signal with nearly the same Ct value 
as the unknown tissue samples, labeled E7-12. 
Again, despite of this, the Comparative Ct Method 
indicates that there are a significant 
downregulation of NDRG2 in the cancer tissues 
E8-12 compared to normal ovarian tissue E7, see 
table 3.  
It is however puzzling that the normal tissue, E7, 
shows a much lower expression of NDRG2 than 
the normal tissue in the cell line experiment, a 
staggering 82.7 % difference in amount. This 
could indicate that the tissue, E7, which is taken 
approximately 5cm from a tumor in a patient, is 
actually in the initial tumor stages despite normal 
appearances.  
 
Alternative splice forms of NDRG2  
It is known that there are two isoforms of 
NDRG2, but their expression hasn’t been 
investigated thoroughly in the research 
community. To our knowledge this is the first 
attempt to show whether there in ovarian cancer 
exits both alternative splice forms of NDRG2.  
This preliminary study shows that there are in 
fact expressed both alternative splice forms, and 
there is an indication of variable interrelations in 
some of the samples and between the samples, 
see figure 3.   
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The gel provides a possible answer towards the 
reoccurrence of contamination in the real-time 
PCR. The PCR product amplified for 30 cycles 
similarly shows a contamination of the negative 
control, which have the same size as the products 
in SKOV-3. However, in the PCR run for 35 cycles, 
the negative control is clean and the PCR product 
of NDRG2 in SKOV-3 is at the same size as the 
PCR run for 30 cycles. This makes it possible to 
deduce that in fact it is a contamination with 
NDRG2 in the negative control. 
 The gel further confirms that there is a relative 
low expression of NDRG2 in ovarian cancer cell 
line compared to normal ovarian tissue. 
Moreover, it is established that there is NDRG2 in 
the E7-E12 tissue samples. Furthermore, despite 
this study cannot quantify it, it seems as though 
there is a difference in expression level of NDRG2 
in the various E-samples.  
 
Discussion  
Regarding NDRG2 expression, a lot of cancers 
have been studied, but some cancer forms have 
been of more interest to investigate NDRG2 
expression in than others, e.g. liver and breast 4,8-
15.  
To our knowledge, ovarian cancer has not been in 
the spotlight, despite of it being a serious illness, 
albeit one study have performed a cancer 
profiling array of NDRG2 in various cancer, 
including ovarian, were it didn’t consistently 
show a downregulation of NDRG2 in ovarian 
cancer4. Contradictory, this pre-study indicates a 
consistency of downregulation in all samples, but 
as in Lorentzen and colleagues, the sample size is 
not ample enough to give a trustworthy result. 
Therefore more clarifying research is needed. 
The significance in investigating whether there is 
a presence of both isoforms of NDRG2 could be 
relevant due to the fact that two isoforms will 
form two different proteins and therefore 
present a suggestion on why pleiotropic functions 
for NDRG2 is seen.   
Intriguingly, several studies have shown that the 
expression level of NDRG2 is inverse correlated 
with tumor stage 7,16,17.  However Furuta and 
colleagues18 did not find such a correlation and 
stretched a bit, this pre-study’ result could 
indicate the same, since the order of samples in 
context of declining NDRG2 level should be E8-
E12 based on tumor stage, but in fact it is E11, E9, 
E10, E12, E8 based on actual declining level of 
measured NDRG2 mRNA. 
In summary, this study points towards more 
research should be designated towards 
illuminating alternative splice forms of NDRG2 in 
Figure 3 PCR products run on agarose gel illustrating 
NDRG2 expression in ovarian cells and tissue. 
Samples in figure A are run at 30 cycles and samples 
in figure B are run at 35 cycles. Sample 1A and 1B are 
blank, 2A and 2B are positive control, 3A and 3B are 
normal ovarian tissue, 4A and 4B are the cell line 
SKOV-3. 5B to 10B are sample E7-E12   
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various cancers, in the quest of obtaining more 
information about NDRG2s diverse functions. 
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Supplementary data 
Validation  
A validation curve is an experiment made to check the amplification efficiency of both the target and the 
endogenous control – hereafter housekeeping gene. This is accomplished when the expression of target 
and housekeeping gene from a standard curve are approximately equal. When equal, it makes it possible to 
rely on the results obtained using the Comparative Ct Method.  When considering the settings of a general 
experiment, three things are important to gain good validation results: 1) the sample must express both 
target and housekeeping genes. 2) The target and the housekeeping gene must be run in separate wells. 3) 
At least 3 replicates for each point in the standard curves.  
The Ct values from the standard curves are used to calculate the ΔCt values (Ct target – Ct housekeeping gene) for the 
validation curve. It is the slope of the semi-log regression line that is used as the validation, and the 
experiment is passed when the slope is <0.1 or approximately 0 (Applied Biosystems).  
 
Validation experiment  
Table S1 Depicts the dilution curve calculated to log values. NDRG2 and RPLP0 Ct average values from the standard curves and 
calculated ΔCt values. 
Diluted Log values NDRG2 [Ct] RPLP0 [Ct] ΔCt  
(Ct NDRG2 – Ct RPLP0) 
Undiluted  1 0 22.1375 14.26 7.8775 
5x 0.2 -0.699 24.055 16.5425 7.5125 
25x 0.04 -1.398 26.195 18.495 7.7 
125x 0.008 -2.097 28.71 21.4125 7.2975 
625x 0.0016 -2.796 31.3475 23.385 7.9625 
3125x 0.00032 -3.495 33.515 25.835 7.68 
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As the validation curve shows, the slope is 0.0016 and therefore <0.1. The validation experiment confirms a 
correct choice of housekeeping gene and the results in the Comparative Ct Method are valid.   
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Validation curve 
Figure S1 Depicts the validation of the housekeeping gene RPLP0 compared to 
NDRG2. 
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Final remarks 
This section will be used to put our work and thoughts into perspective.  
Our preliminary data cannot be used to state anything significant about an inverse correlation between 
NDRG2 and tumor stage, but it may give an indication of the lacking ability to say something consistent 
about TNM and level of NDRG2 in ovarian cancer. 
In our preliminary study it was shown that both alternative splice forms of NDRG2 were expressed in 
ovarian cancer cell line and tissues. Other studies have in their results indicated, during Western Blotting, 
the presence of two bands in close proximity, see table 1. They do not however comment on these findings 
and we contemplate that there could be some uncertainties combined with interpretation of these bands 
as being NDRG2, since the antibodies could have bound the other NDRG proteins. We therefore suggest 
more designated research into isoforms of NDRG2 in cancers, since they theoretically could have different 
functions due to difference in folding. 
 
Table 1 Comprising articles showing two bands in close proximity obtained by either 
gel electrophoresis or Western Blotting.  
Cancer NDRG2 
mRNA 
in cell lines 
NDRG2 
protein in 
cell lines 
NDRG2 
protein in 
tissues  
Source 
Esophageal 
squamous 
- + + (35) 
Neuroblastoma + + - (36) 
Colorectal + + + (37) 
Liver - + - (38) 
Liver - + - (39) 
Liver - + - (40) 
 
It could seem to be positive that there has been found an upregulating mechanism for NDRG2 by Cisplatin, 
but this should be viewed in context of a diminished ability of Cisplatin-induced apoptosis41. This is 
therefore contradictory to all of the other studies which show that upregulated NDRG2 correlates with 
functions related to inhibition of cancer progression. A question now arises: can Cisplatin be used as an 
upregulator for NDRG2, where it will have so much positive effects for the patient that the diminished 
apoptosis will be an accepted side effect?  
Another question worth investigating is whether it is possible to state something consistent about how 
NDRG2 functions. Studies done since 2010 which have focused on elucidating NDRG2 functions in tissue, is 
all done in tissues from Asian patients. In the light of other known ethnic discrepancy in the medical field, 
we question whether this might be the same for NDRG2. A study shows that the expression of NDRG1 is the 
same in Japanese, Chinese and Caucasian patients, but the functionality is different. The study compared 
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and found for Japanese and Chinese patients there were a positive correlation between NDRG1 and 
metastasis and for the Caucasian patients there were a negative correlation with metastasis42. On the basis 
of this, studies with different ethnicity are needed to shed light on the issue regarding NDRG2 functions as 
well as its ability to be a universal biomarker for all ethnicities.  
In the review there are listed 23 articles who investigate NDRG2 expression in tissue, and out of these a 
staggering 21 have tissue samples from Asian patients. This could similar raise a question on whether 
NDRG2 expression profile and hence the statement that NDRG2 could be a TS-gene, is viable in other 
ethnicities. 
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Appendix  
Protocols for laboratory work 
This study is focusing on determination of NDRG2 expression level in ovarian cancer cells and elucidating 
isoforms of NDRG2 in the same. This is done by real-time PCR, performed with Agilent Technologies, and 
ordinary PCR followed by gel electrophoresis, respectively. The results in real-time PCR are relative to 
NDRG2 expression in liver cells and normalized to an endogenous control, RPLP0 also called housekeeping 
gene.  
 
Standard curve 
A standard curve for NDRG2 in liver cDNA is produced to choose a positive control and check the chosen 
primers efficiency. A standard curve for RPLP0 in liver cDNA is produced to check the chosen primers 
efficiency, validate the chosen housekeeping gene and to obtain a constant expression to which we can 
normalize the following samples against.  
A dilution series was done to obtain 5x, 25x, 125x, 625x and 3125x dilutions of liver cDNA.  
A Master Mix (MM) was done with NDRG2 and RPLP0 primers, respectively: 
150µL Quantitect SYBR Green I PCR Master Mix (QIAGEN #204141) 
   30µL Forward primer NDRG2 (5’-GCTACAACAACCGCCGAGAC-3’) 
   30µL Reverse primer NDRG2 (5’-ACAGGCGAGTCATGCAGGAT-3’) 
   60µL Nuclease-free H2O 
 
150µL Quantitect SYBR Green I PCR Master Mix (QIAGEN #204141) 
   30µL Forward primer RPLP0 (5’-GCTTCCTGGAGGGTGTCC-3’) 
   30µL Reverse primer RPLP0 (5’-GGACTCGTTTGTACCCGTTG-3’) 
   60µL Nuclease-free H2O 
 
Each standard curve is done in duplicates: 
  Blank/H2O Undiluted 5x 
diluted 
25x 
diluted 
125x 
diluted 
625x 
diluted 
3125x 
diluted 
2x NDRG2 
primer 
1µL 
template + 
 9µL MM 
1µL 
template + 
9µL MM 
1µL 
template 
+ 9µL MM 
1µL 
template 
+ 9µL MM 
1µL 
template 
+ 9µL MM 
1µL 
template 
+ 9µL MM 
1µL 
template 
+ 9µL MM 
2x PRLP0 
primer 
1µL 
template +  
9µL MM 
1µL 
template + 
9µL MM 
1µL 
template 
+ 9µL MM 
1µL 
template 
+ 9µL MM 
1µL 
template 
+ 9µL MM 
1µL 
template 
+ 9µL MM 
1µL 
template 
+9µL MM 
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Real-time PCR program for NDRG2 primers 
One cycle of 15 min at 95oC for initiation of enzyme activity, 45 cycles of 15 sec at 95oC for denaturation, 30 
sec at 55oC for annealing, 30 sec at 72oC for elongation. 
Melting curve program for NDRG2 primers 
Following was performed for each real-time PCR: 95oC for 15 sec, 55oC for 30 sec and 95oC for 30 sec. 
Real-time PCR program for RPLP0 primers 
One cycle of 15 min at 95oC for initiation of enzyme activity, 45 cycles of 15 sec at 95oC for denaturation, 15 
sec at 52oC for annealing, 30 sec at 72oC for elongation. 
Melting curve program for RPLP0 primers 
Following was performed for each real-time PCR: 95oC for 15 sec, 52oC for 30 sec and 95oC for 30 sec. 
 
Real-time PCR for ovarian cell lines 
To obtain level of NDRG2 expression in normal ovarian cells, cDNA obtained from human MTC Panel II, 
catalog no. 636743 and lot no. 1204481A, and ovarian cancer cells, cDNA obtained from MTC Panel, catalog 
no. 636753 and lot no. 6090253, following was performed.  
A Master Mix (MM) was done with NDRG2 and RPLP0 primers, respectively:  
 60µL Quantitect SYBR Green I PCR Master Mix (QIAGEN #204141) 
 14µL Forward primer NDRG2 (5’-GCTACAACAACCGCCGAGAC-3’) 
 14µL Reverse primer NDRG2 (5’-ACAGGCGAGTCATGCAGGAT-3’) 
 28µL Nuclease-free H2O 
 
60µL Quantitect SYBR Green I PCR Master Mix (QIAGEN #204141) 
14µL Forward primer RPLP0 (5’-GCTTCCTGGAGGGTGTCC-3’) 
14µL Reverse primer RPLP0 (5’-GGACTCGTTTGTACCCGTTG-3’) 
28µL Nuclease-free H2O 
 
Each reaction is done in triplicates: 
  Blank/H2O 25x diluted 
liver cDNA 
10x diluted 
ovarian cDNA 
10x diluted 
SKOV-3 cDNA 
3x NDRG2 primer 1µL template +  
9µL MM 
1µL template +  
9µL MM 
1µL template +  
9µL MM 
1µL template +  
9µL MM 
3x RPLP0 primer 1µL template +  
9µL MM 
1µL template +  
9µL MM 
1µL template +  
9µL MM 
1µL template + 
 9µL MM 
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Real-time PCR program for NDRG2 
One cycle of 15 min at 95oC for initiation of enzyme activity, 45 cycles of 15 sec at 95oC for denaturation, 30 
sec at 55oC for annealing, 30 sec at 72oC for elongation. 
Real-time PCR program for RPLP0 
One cycle of 15 min at 95oC for initiation of enzyme activity, 45 cycles of 15 sec at 95oC for denaturation, 15 
sec at 52oC for annealing, 30 sec at 72oC for elongation. 
 
Real-time PCR for ovarian tissue 
To obtain level of NDRG2 expression in ovarian tissue obtained from Origene with sample ID: RN0000358A 
(E7), RN000036DD (E8), RN0000356D (E9), RN0000360F (E10), RN000035F6 (E11), RN000036DB (E12), 
following was performed. 
A Master Mix (MM) was done with NDRG2 and RPLP0 primers, respectively. 
125µL Quantitect SYBR Green I PCR Master Mix (QIAGEN #204141) 
  25µL Forward primer NDRG2 (5’-GCTACAACAACCGCCGAGAC-3’) 
  25µL Reverse primer NDRG2 (5’-ACAGGCGAGTCATGCAGGAT-3’) 
  50µL Nuclease-free H2O 
 
125µL Quantitect SYBR Green I PCR Master Mix (QIAGEN #204141) 
  25µL Forward primer RPLP0 (5’-GCTTCCTGGAGGGTGTCC-3’) 
  25µL Reverse primer RPLP0 (5’-GGACTCGTTTGTACCCGTTG-3’) 
  50µL Nuclease-free H2O 
 
Each reaction is done in triplicates: 
  Blank/ 
H2O 
25x liver 
cDNA 
E7 E8 E9 E10 E11 E12 
3x NDRG2 
primer 
1µL 
template 
+ 
9µL MM 
1µL         
template 
+ 
9µL MM 
1µL 
template 
+ 
9µL MM 
1µL 
template 
+ 
9µL MM 
1µL 
template 
+ 
9µL MM 
1µL 
template 
+ 
9µL MM 
1µL 
template 
+ 
9µL MM 
1µL 
template 
+ 
9µL MM 
3x RPLP0 
primer 
1µL 
template 
+ 
9µL MM 
1µL 
template 
+ 
9µL MM 
1µL 
template 
+ 
9µL MM 
1µL 
template 
+ 
9µL MM 
1µL 
template 
+ 
9µL MM 
1µL 
template 
+ 
9µL MM 
1µL 
template 
+ 
9µL MM 
1µL 
template 
+ 
9µL MM 
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Real-time PCR program for NDRG2 
One cycle of 15 min at 95oC for initiation of enzyme activity, 45 cycles of 15 sec at 95oC for denaturation, 30 
sec at 55oC for annealing, 30 sec at 72oC for elongation. 
Real-time PCR program for RPLP0 
One cycle of 15 min at 95oC for initiation of enzyme activity, 45 cycles of 15 sec at 95oC for denaturation, 15 
sec at 52oC for annealing, 30 sec at 72oC for elongation. 
 
PCR and gel electrophoresis  
To elucidate the presence of NDRG2 isoforms in ovarian tissue, same tissue as used in previous experiment, 
PCR was performed and visualized by gel electrophoresis. 
Firstly, a 250x dilution of liver cDNA, same as used in previous experiment, and 100x dilution of ovarian 
cDNA was done to minimize intensity of the band, when run in the gel. 
Master Mix to all 22 reactions was prepared at once, to minimize errors. 
 
220µL Maxima Hot Start Master Mix  
  22µL Forward primer NDRG2 (5’-CACCATGGCGGAGCTGCAGGAG-3’)  
  22µL Reverse primer NDRG2 (5’-AAGGGATCATGTCTGCAAGCTGGTC-3’) 
132µL Sterile H2O 
There was done no replication of this experiment. 
 
Following is the samples run on different PCR settings, see table on the next page:  
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 30 cycles 35 cycles 
Blank/H2O 2µL template + 
18µL MM 
2µL template + 
18µL MM 
25x liver cDNA 2µL template + 
18µL MM 
2µL template + 
18µL MM 
10x ovarian cDNA 2µL template + 
18µL MM 
2µL template + 
18µL MM 
10x SKOV-3 cDNA 2µL template + 
18µL MM 
2µL template + 
18µL MM 
E7 2µL template + 
18µL MM 
2µL template + 
18µL MM 
E8 2µL template + 
18µL MM 
2µL template + 
18µL MM 
E9 2µL template + 
18µL MM 
2µL template + 
18µL MM 
E10 2µL template + 
18µL MM 
2µL template + 
18µL MM 
E11 2µL template + 
18µL MM 
2µL template + 
18µL MM 
E12 2µL template + 
18µL MM 
2µL template + 
18µL MM 
 
PCR settings 
1 cycle 94oC 4 min 
5 cycles 94oC 30 sec, 68oC 30 sec, 72oC 1 min 
30/35 cycles 94oC 30 sec, 64oC 30 sec, 72oC 1 min 
1 cycle 72oC 5 min 
1 cycle 10oC 
 
Gel casting 
A 1.4 % agarose gel was casted by mixing 1.4g agarose and 100mL 1xTBE. There was added 10µL Ethidium 
Bromide to the gel, to add a fluorescent tag to the PCR product. 
To each PCR sample, 5µL loading buffer was mixed, and 12.5µL of each sample was placed in separate 
wells, flanked by 7.5µL gene ruler from Fermentas, sm1333, and 10µL Ethidium Bromide was added to the 
running 1xTBE buffer. 
The gel was run at 120V and viewed indirectly under UV-light using an enclosed camera.  
60 
 
Real-time PCR  
The purpose for real-time PCR is to measure gene expression and it is a lot more complex than traditional 
PCR. Traditional PCR has 3 phases: denaturation of dsDNA, annealing of primers and amplification. First the 
cDNA is denaturized at 94-96°C, then the temperature is cooled down to 50-60°C to allow the primers to 
anneal with the DNA strand and then the temperature is raised to 68-72°C for the amplification. These 
three steps are repeated for 30 to 40 cycles, to multiply the number of cDNA copies. Measuring gene 
expression with real-time PCR can be one of the most efficient, fast and sensitive methods, when the 
experiment is designed properly. There are several ways to perform real-time PCR and here two-step real-
time RT-PCR, relative quantitation, normalisation to a housekeeping gene and SYBR Green I will be in focus. 
Generally there are four phases in a real-time PCR reaction: linear ground phase, early exponential phase, 
exponential phase and plateau phase. The first 10 to 15 cycles are the linear ground phase, where the 
fluorescence emission has not increased beyond background, which is where all dsDNA emits fluorescence 
with SYBR Green I. In the early exponential phase, fluorescence will then reach threshold, referred to as Ct, 
which is significantly higher than the background levels. In ideal reaction conditions the PCR product will 
double after each cycle and it is where PCR will reach its optimal amplification period in the exponential or 
log-linear phase. When the components of the reaction are limited it will reach the plateau phase43.   
Two-step real-time RT-PCR refers to the separation of reverse transcription and real-time PCR. This means 
that it occurs in two different tubes compared to one-step real-time RT-PCR, where the whole reaction 
occurs in one tube. One of the advantages for two-step real-time RT-PCR is that it is possible to use the 
dilutions subsequently and be sure that it has the same amount of template all the way through43. 
Relative quantitation makes it possible to quantify differences in the expression level of a specific gene 
between different samples, and the data for expression levels is expressed as a fold-change (Applied 
Biosystems). The gene expression changes are measured against a calibrator, that is a reference sample and 
this will be expressed as a target/reference ratio43. It is also recommended to use an endogenous control, 
also known as a housekeeping gene, to get the most accurate relative quantitation of an mRNA target 
(Applied Biosystems). This means that the target gene is normalized against the housekeeping gene and 
then this is held up against the calibrator for a relative result.  An endogenous control is used to normalize 
gene expression43 (Applied Biosystems).   
SYBR Green I is a DNA binding dye. It is a fluorescent dye and it binds to all double stranded DNA at the 
minor groove. When bound and excited by a light source it will emit fluorescence proportional to the 
dsDNA concentration43 (Applied Biosystems). The intensity of the fluorescent dye will be measured after 
each cycle, therefore real-time (SYBR Green handbook). One thing that is essential for this procedure is the 
master mix: The polymerase is HotStarTaq DNA Polymerase, which gives high specificity and sensitivity 
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together with a buffer that is specialized to PCR. To activate this enzyme, incubation at 95°C for 15 minutes 
is required. A passive reference dye like ROX is usually incorporated in the master mix and in SYBR Green I it 
is in the buffer. This is to check for small differences in PCR master mix volumes and for non-PCR-related 
fluctuations in fluorescence signal43 (SYBR Green handbook).  
 
The Comparative Ct Method  
The comparative Ct Method, also known as the ΔΔCt Method, is a mathematical model for calculating the 
changes in the gene expression. This is done by a relative fold difference between the experimental sample 
and the calibrator43 (Applied Biosystems). 
The arithmetic formula where the amount of target, is normalized to an endogenous reference and relative 
to a calibrator, is given by:  
       
To be sure that the comparative Ct Method is valid, the efficiency of the gene amplification and the 
efficiency of the housekeeping gene amplification must be approximately equal, see supplementary data in 
the back of the original article.  
 
Real-time PCR graphs  
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